(PLXS) Plexus - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7291321005
Stock: Electronics, Manufacturing, Aerospace, Healthcare, Industrial
Total Rating 56
Risk 86
Buy Signal 1.73
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 51.9% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.92 |
| Alpha | 17.32 |
| Character TTM | |
|---|---|
| Beta | 1.269 |
| Beta Downside | 1.406 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.92% |
| CAGR/Max DD | 0.74 |
Description: PLXS Plexus January 12, 2026
Plexus Corp. (NASDAQ: PLXS) is a global provider of electronic manufacturing services (EMS), delivering design, development, supply-chain management, new-product introduction, and sustaining production across the United States, Asia-Pacific, Europe, the Middle East, and Africa.
The company’s end-market focus includes aerospace & defense, healthcare & life sciences, and industrial/commercial sectors, positioning it to benefit from rising defense budgets (U.S. defense spending grew ~3.5% YoY in FY2023) and the accelerating adoption of medical-device electronics.
Key operating metrics from the most recent fiscal year show revenue of approximately $2.2 billion, an adjusted EBITDA margin near 7.5%, and a backlog of roughly $1.1 billion-indicating a solid order pipeline but also exposing the firm to the ongoing semiconductor supply constraints that have pressured EMS margins industry-wide.
Strategically, Plexus is pursuing nearshoring initiatives to mitigate supply-chain risk and capture higher-margin work in the U.S., a trend reinforced by recent policy incentives for domestic electronics manufacturing.
For a deeper, data-driven look at PLXS’s valuation metrics, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 172.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -5.91 > 1.0 |
| NWC/Revenue: 21.82% < 20% (prev 21.05%; Δ 0.77% < -1%) |
| CFO/TA 0.08 > 3% & CFO 249.2m > Net Income 172.9m |
| Net Debt (-131.3m) to EBITDA (277.4m): -0.47 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.4m) vs 12m ago -1.22% < -2% |
| Gross Margin: 10.08% > 18% (prev 0.10%; Δ 998.4% > 0.5%) |
| Asset Turnover: 128.2% > 50% (prev 125.6%; Δ 2.63% > 0%) |
| Interest Coverage Ratio: 17.20 > 6 (EBITDA TTM 277.4m / Interest Expense TTM 11.6m) |
Altman Z'' 5.60
| A: 0.28 (Total Current Assets 2.40b - Total Current Liabilities 1.52b) / Total Assets 3.14b |
| B: 0.64 (Retained Earnings 2.00b / Total Assets 3.14b) |
| C: 0.06 (EBIT TTM 199.6m / Avg Total Assets 3.15b) |
| D: 1.20 (Book Value of Equity 2.01b / Total Liabilities 1.68b) |
| Altman-Z'' Score: 5.60 = AAA |
Beneish M -2.92
| DSRI: 1.07 (Receivables 807.2m/742.9m, Revenue 4.03b/3.96b) |
| GMI: 0.95 (GM 10.08% / 9.56%) |
| AQI: 1.19 (AQ_t 0.04 / AQ_t-1 0.03) |
| SGI: 1.02 (Revenue 4.03b / 3.96b) |
| TATA: -0.02 (NI 172.9m - CFO 249.2m) / TA 3.14b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of PLXS shares?
As of January 30, 2026, the stock is trading at USD 197.60 with a total of 859,778 shares traded.
Over the past week, the price has changed by +9.01%, over one month by +30.61%, over three months by +41.68% and over the past year by +37.78%.
Over the past week, the price has changed by +9.01%, over one month by +30.61%, over three months by +41.68% and over the past year by +37.78%.
Is PLXS a buy, sell or hold?
Plexus has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold PLXS.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PLXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 159 | -19.5% |
| Analysts Target Price | 159 | -19.5% |
| ValueRay Target Price | 242.6 | 22.7% |
PLXS Fundamental Data Overview January 29, 2026
P/E Trailing = 27.7173
P/S = 1.1519
P/B = 3.2357
P/EG = 1.61
Revenue TTM = 4.03b USD
EBIT TTM = 199.6m USD
EBITDA TTM = 277.4m USD
Long Term Debt = 92.0m USD (from longTermDebt, last quarter)
Short Term Debt = 54.0m USD (from shortTermDebt, last quarter)
Debt = 175.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -131.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.51b USD (4.65b + Debt 175.5m - CCE 306.8m)
Interest Coverage Ratio = 17.20 (Ebit TTM 199.6m / Interest Expense TTM 11.6m)
EV/FCF = 29.32x (Enterprise Value 4.51b / FCF TTM 154.0m)
FCF Yield = 3.41% (FCF TTM 154.0m / Enterprise Value 4.51b)
FCF Margin = 3.82% (FCF TTM 154.0m / Revenue TTM 4.03b)
Net Margin = 4.29% (Net Income TTM 172.9m / Revenue TTM 4.03b)
Gross Margin = 10.08% ((Revenue TTM 4.03b - Cost of Revenue TTM 3.63b) / Revenue TTM)
Gross Margin QoQ = 9.90% (prev 10.14%)
Tobins Q-Ratio = 1.44 (Enterprise Value 4.51b / Total Assets 3.14b)
Interest Expense / Debt = 1.38% (Interest Expense 2.41m / Debt 175.5m)
Taxrate = 8.05% (15.1m / 188.0m)
NOPAT = 183.6m (EBIT 199.6m * (1 - 8.05%))
Current Ratio = 1.58 (Total Current Assets 2.40b / Total Current Liabilities 1.52b)
Debt / Equity = 0.12 (Debt 175.5m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -0.47 (Net Debt -131.3m / EBITDA 277.4m)
Debt / FCF = -0.85 (Net Debt -131.3m / FCF TTM 154.0m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.50% (Net Income 172.9m / Total Assets 3.14b)
RoE = 12.47% (Net Income TTM 172.9m / Total Stockholder Equity 1.39b)
RoCE = 13.51% (EBIT 199.6m / Capital Employed (Equity 1.39b + L.T.Debt 92.0m))
RoIC = 11.76% (NOPAT 183.6m / Invested Capital 1.56b)
WACC = 10.25% (E(4.65b)/V(4.82b) * Re(10.59%) + D(175.5m)/V(4.82b) * Rd(1.38%) * (1-Tc(0.08)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.02%
[DCF Debug] Terminal Value 65.41% ; FCFF base≈228.9m ; Y1≈180.7m ; Y5≈119.3m
Fair Price DCF = 63.49 (EV 1.57b - Net Debt -131.3m = Equity 1.70b / Shares 26.8m; r=10.25% [WACC]; 5y FCF grow -25.11% → 2.90% )
EPS Correlation: 58.85 | EPS CAGR: 26.74% | SUE: 2.20 | # QB: 2
Revenue Correlation: 30.16 | Revenue CAGR: 7.13% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.37 | Chg30d=+0.000 | Revisions Net=-4 | Growth EPS=-0.8% | Growth Revenue=+8.6%
EPS next Year (2027-09-30): EPS=8.20 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+11.2% | Growth Revenue=+6.7%
P/S = 1.1519
P/B = 3.2357
P/EG = 1.61
Revenue TTM = 4.03b USD
EBIT TTM = 199.6m USD
EBITDA TTM = 277.4m USD
Long Term Debt = 92.0m USD (from longTermDebt, last quarter)
Short Term Debt = 54.0m USD (from shortTermDebt, last quarter)
Debt = 175.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -131.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.51b USD (4.65b + Debt 175.5m - CCE 306.8m)
Interest Coverage Ratio = 17.20 (Ebit TTM 199.6m / Interest Expense TTM 11.6m)
EV/FCF = 29.32x (Enterprise Value 4.51b / FCF TTM 154.0m)
FCF Yield = 3.41% (FCF TTM 154.0m / Enterprise Value 4.51b)
FCF Margin = 3.82% (FCF TTM 154.0m / Revenue TTM 4.03b)
Net Margin = 4.29% (Net Income TTM 172.9m / Revenue TTM 4.03b)
Gross Margin = 10.08% ((Revenue TTM 4.03b - Cost of Revenue TTM 3.63b) / Revenue TTM)
Gross Margin QoQ = 9.90% (prev 10.14%)
Tobins Q-Ratio = 1.44 (Enterprise Value 4.51b / Total Assets 3.14b)
Interest Expense / Debt = 1.38% (Interest Expense 2.41m / Debt 175.5m)
Taxrate = 8.05% (15.1m / 188.0m)
NOPAT = 183.6m (EBIT 199.6m * (1 - 8.05%))
Current Ratio = 1.58 (Total Current Assets 2.40b / Total Current Liabilities 1.52b)
Debt / Equity = 0.12 (Debt 175.5m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -0.47 (Net Debt -131.3m / EBITDA 277.4m)
Debt / FCF = -0.85 (Net Debt -131.3m / FCF TTM 154.0m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.50% (Net Income 172.9m / Total Assets 3.14b)
RoE = 12.47% (Net Income TTM 172.9m / Total Stockholder Equity 1.39b)
RoCE = 13.51% (EBIT 199.6m / Capital Employed (Equity 1.39b + L.T.Debt 92.0m))
RoIC = 11.76% (NOPAT 183.6m / Invested Capital 1.56b)
WACC = 10.25% (E(4.65b)/V(4.82b) * Re(10.59%) + D(175.5m)/V(4.82b) * Rd(1.38%) * (1-Tc(0.08)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.02%
[DCF Debug] Terminal Value 65.41% ; FCFF base≈228.9m ; Y1≈180.7m ; Y5≈119.3m
Fair Price DCF = 63.49 (EV 1.57b - Net Debt -131.3m = Equity 1.70b / Shares 26.8m; r=10.25% [WACC]; 5y FCF grow -25.11% → 2.90% )
EPS Correlation: 58.85 | EPS CAGR: 26.74% | SUE: 2.20 | # QB: 2
Revenue Correlation: 30.16 | Revenue CAGR: 7.13% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.37 | Chg30d=+0.000 | Revisions Net=-4 | Growth EPS=-0.8% | Growth Revenue=+8.6%
EPS next Year (2027-09-30): EPS=8.20 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+11.2% | Growth Revenue=+6.7%